OTCMKTS:AGYTF - Allergy Therapeutics Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.17
0.00 (0.00 %)
(As of 02/22/2019)
Today's Range
$0.17
Now: $0.17
$0.17
50-Day Range N/A
52-Week Range
$0.17
Now: $0.17
$0.1880
Volume1,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.75
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. Read More…

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AGYTF
Previous SymbolNASDAQ:AGYTF
CUSIPN/A
CIKN/A
Phone44-19-0384-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$92.06 million
Book Value$0.05 per share

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AGYTF News and Ratings via Email

Sign-up to receive the latest news and ratings for AGYTF and its competitors with MarketBeat's FREE daily newsletter.

Allergy Therapeutics (OTCMKTS:AGYTF) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the OTCMKTS under the ticker symbol "AGYTF."

Has Allergy Therapeutics been receiving favorable news coverage?

Media coverage about AGYTF stock has trended negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergy Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Allergy Therapeutics.

Who are some of Allergy Therapeutics' key competitors?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

What is Allergy Therapeutics' stock price today?

One share of AGYTF stock can currently be purchased for approximately $0.17.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way West Sussex, Worthing X0, BN14 8SA. The company can be reached via phone at 44-19-0384-4700.


MarketBeat Community Rating for Allergy Therapeutics (OTCMKTS AGYTF)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGYTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGYTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel